Clinical effectiveness of coronavirus disease 2019 vaccination in patients with multiple sclerosis stratified by disease‐modifying treatment
European Journal of Neurology · 2024
DOI: 10.1111/ene.16300 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Marijke De Troyer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. Hauptthemen laut MEDLINE: COVID-19, Multiple Sclerosis, COVID-19 Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and purpose Coronavirus disease 2019 (COVID‐19) vaccination has been associated with a dampened humoral and/or cellular immune response in patients with multiple sclerosis (MS) who were concurrently on disease‐modifying treatment (DMT) with B‐cell depleting agents or sphingosine‐1‐phosphate receptor modulators (S1PRMs). Our main goal was to investigate the impact of these DMT classes on the clinical effectiveness of COVID‐19 vaccination.
Methods
Since March 2020, demographics and clinical data of patients with MS who developed COVID‐19 have been collected at the Belgian National MS Centre in Melsbroek. Patients were considered to be ‘protected by vaccination’ if they were (i) fully vaccinated and (ii) tested positive for COVID‐19 in the period ranging from 14 days to 6 months after the last administered vaccine.
Results
On 19 December 2022, 418 COVID‐19 cases were retrospectively identified in 389 individual patients. Hospitalization and mortality rates resulting from the infection were 10.8% and 2.4%, respectively. Being ‘unprotected by vaccination’ was significantly associated with a worse COVID‐19 outcome (i.e., hospitalization and/or death) in the total cohort ( N = 418, odds ratio [OR] 3.96), in patients on ongoing DMT other than anti‐CD20 agents or S1PRMs ( N = 123, OR 31.75) and in patients without DMT ( N = 182, OR 5.60), but not in those receiving anti‐CD20 agents ( N = 91, OR 0.39); the S1PRMs subgroup was considered too small (22 infections) for any meaningful analysis.
Conclusions
Coronavirus disease 2019 vaccination protects against severe infection in patients with MS but it was not possible to confirm this effect in those on DMT with B‐cell depleting agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
- Department of Neurology, Onze-Lieve-Vrouw Ziekenhuis (OLVZ), Aalst, Belgium.
- Nationaal Multiple Sclerose Centrum (NMSC), Melsbroek, Belgium.
- Neuroprotection and Neuromodulation (NEUR) Research Groups, Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
- Artificial Intelligence supported Modelling in clinical Sciences (AIMS) Research Groups, Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
- Department of Electronics and Informatics (ETRO), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Zitieren
APA
De Troyer, M., Van Remoortel, A., Van Schependom, J., Faille, L. D., D'hooghe, M. B., Peeters, G., Nagels, G., & D'haeseleer, M. (2024). Clinical effectiveness of coronavirus disease 2019 vaccination in patients with multiple sclerosis stratified by disease‐modifying treatment. European Journal of Neurology. https://doi.org/10.1111/ene.16300
Vancouver
De Troyer M, Van Remoortel A, Van Schependom J, Faille LD, D'hooghe MB, Peeters G, et al. Clinical effectiveness of coronavirus disease 2019 vaccination in patients with multiple sclerosis stratified by disease‐modifying treatment. European Journal of Neurology. 2024. doi:10.1111/ene.16300
BibTeX
@article{DeTroyer2024,
author = {De Troyer, Marijke and Van Remoortel, Ann and Van Schependom, Jeroen and Faille, Laetitia Della and D'hooghe, Marie B and Peeters, Gertjan and Nagels, Guy and D'haeseleer, Miguel},
title = {Clinical effectiveness of coronavirus disease 2019 vaccination in patients with multiple sclerosis stratified by disease‐modifying treatment},
journal = {European Journal of Neurology},
year = {2024},
doi = {10.1111/ene.16300}
}
EUVIMED